Sept. 26, 2007 – Spiration, Inc., a developer of novel medical technology designed to benefit patients with acute and chronic conditions of the lung, today announced that the first patients have been enrolled in the company’s IBV Valve Trial in the United States. The purpose of the trial is to generate safety and effectiveness data for submission to the U.S. Food and Drug Administration (FDA) for approval to market the company’s IBV Valve System in the United States for the treatment of patients with severe emphysema... Spiration's Press Release [PDF] -
Sep 28, 2007
Spiration, U.S. Pivotal Trial of Minimally Invasive Treatment for Severe Emphysema
Sept. 26, 2007 – Spiration, Inc., a developer of novel medical technology designed to benefit patients with acute and chronic conditions of the lung, today announced that the first patients have been enrolled in the company’s IBV Valve Trial in the United States. The purpose of the trial is to generate safety and effectiveness data for submission to the U.S. Food and Drug Administration (FDA) for approval to market the company’s IBV Valve System in the United States for the treatment of patients with severe emphysema... Spiration's Press Release [PDF] -
